Professor Geraint Davies BM PhD FRCP DTM&H

Professor of Infection Pharmacology Clinical Infection, Microbiology & Immunology

Research

Research Overview

My research focuses on improving the treatment of tuberculosis, ranging from evaluation of the value of preclinical models through pharmacokinetic-pharmacodynamic studies and clinical trials to evidence synthesis and policy.

Research Group Membership

Research Grants

Academia and Industry United Innovation and Treatment for Tuberculosis ( UNITE4TB)

EUROPEAN COMMISSION

June 2021 - May 2028

PanACEA Biomarker Extension Project (PANBIOME)

EDCTP (NETHERLANDS)

January 2013 - June 2015

Randomised trial of high-dose rifampin in patients with new, smear-positive TB

NATIONAL INSTITUTES OF HEALTH (NIH) (USA)

August 2011 - July 2017

Model-based preclinical development of anti-tuberculosis drug combinations (preDICT-TB)

EUROPEAN COMMISSION

May 2012 - October 2017

Population pharmacokinetic-pharmacodynamic modelling to optimise treatments for HIV,TB and malaria

WELLCOME TRUST (UK)

November 2008 - October 2012

Modulation of TB-HIV drug interaction by host genetic influences

MEDICAL RESEARCH COUNCIL (MRC)

July 2010 - June 2013

Wellcome Trust Clinical PhD Programme - Derek Sloan: Understanding mycobacterial persistence in sputum during treatment for tuberculosis

WELLCOME TRUST (UK)

August 2009 - July 2012

Investigation into the relationship between pharmacological and immunological responses to tuberculosis treatment and risk of early death

THE BRITISH INFECTION ASSOCIATION (UK)

January 2013 - August 2014

Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a multi-centre, randomised, double blind, placebo controlled trial (the ARREST trial).

DEPARTMENT OF HEALTH & SOCIAL CARE (UK) (DOH/DHSC/NIHR)

October 2012 - June 2016